← Back to Search

MOCS for Communication

N/A
Waitlist Available
Led By J. Matthias Walz, MD
Research Sponsored by J. Matthias Walz
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects who are awake with a Glasgow Coma Scale score >10 (Motor 6, Verbal 0-1 [T], Eye opening 4) adult subjects at UMass Medical Center (Memorial and University ICUs) or at MGH (Bigelow 13, Lunder 6, Blake 7, Blake 12, or Ellison 4) are eligible for this study.
Both subjects who are able to speak and subjects who are unable to speak (due to intubation or tracheostomy) will be sought to be included in the study, although the focus will be on subjects who are unable to speak. (If additional feedback about the system from subjects who can speak would be helpful, this type of subject may be enrolled.)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This study is evaluating whether a new communication device may help patients in the intensive care unit.

Eligible Conditions
  • Communication
  • Ventilation Therapy Complications

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ability to use make selections in software using handheld component
Secondary outcome measures
Duration of use
Level of engagement
Satisfaction assessed by modified SUS

Trial Design

1Treatment groups
Experimental Treatment
Group I: Use of MOCS with post-use interviewExperimental Treatment2 Interventions
The patients in this arm will be asked to utilize the Manually Operated Communication System (MOCS) device and will then be asked to provide feedback on their experiences. Subjects will be asked to complete up to 3 sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, the session may last up to one hour. The study team will perform post-study interviews with each subject to ask about their experience with MOCS. The data collection forms will be filled out during the session by a member of the research team.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MOCS
2018
N/A
~20

Find a Location

Who is running the clinical trial?

J. Matthias WalzLead Sponsor
1 Previous Clinical Trials
13 Total Patients Enrolled
Brown UniversityOTHER
452 Previous Clinical Trials
562,141 Total Patients Enrolled
1 Trials studying Communication
27 Patients Enrolled for Communication
J. Matthias Walz, MDPrincipal Investigator - UMass Medical School
University of Massachusetts, Worcester
1 Previous Clinical Trials
27 Total Patients Enrolled
1 Trials studying Communication
27 Patients Enrolled for Communication

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025